480 related articles for article (PubMed ID: 12065434)
41. MDR1 and BCRP Transporter-Mediated Drug-Drug Interaction between Rilpivirine and Abacavir and Effect on Intestinal Absorption.
Reznicek J; Ceckova M; Ptackova Z; Martinec O; Tupova L; Cerveny L; Staud F
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696229
[TBL] [Abstract][Full Text] [Related]
42. Pharmacogenetics of irinotecan metabolism and transport: an update.
Smith NF; Figg WD; Sparreboom A
Toxicol In Vitro; 2006 Mar; 20(2):163-75. PubMed ID: 16271446
[TBL] [Abstract][Full Text] [Related]
43. Characterization of P-glycoprotein mediated transport of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor, across MDR1-MDCK and Caco-2 cell monolayers.
Zhang Y; Benet LZ
Pharm Res; 1998 Oct; 15(10):1520-4. PubMed ID: 9794492
[TBL] [Abstract][Full Text] [Related]
44. Differential roles of P-glycoprotein, multidrug resistance-associated protein 2, and CYP3A on saquinavir oral absorption in Sprague-Dawley rats.
Usansky HH; Hu P; Sinko PJ
Drug Metab Dispos; 2008 May; 36(5):863-9. PubMed ID: 18256206
[TBL] [Abstract][Full Text] [Related]
45. Are MDCK cells transfected with the human MRP2 gene a good model of the human intestinal mucosa?
Tang F; Horie K; Borchardt RT
Pharm Res; 2002 Jun; 19(6):773-9. PubMed ID: 12134946
[TBL] [Abstract][Full Text] [Related]
46. The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions.
Polli JW; Humphreys JE; Harmon KA; Castellino S; O'Mara MJ; Olson KL; John-Williams LS; Koch KM; Serabjit-Singh CJ
Drug Metab Dispos; 2008 Apr; 36(4):695-701. PubMed ID: 18216274
[TBL] [Abstract][Full Text] [Related]
47. Modulation of liver canalicular transport processes by the tyrosine-kinase inhibitor genistein: implications of genistein metabolism in the rat.
Jäger W; Winter O; Halper B; Salamon A; Sartori M; Gajdzik L; Hamilton G; Theyer G; Graf J; Thalhammer T
Hepatology; 1997 Dec; 26(6):1467-76. PubMed ID: 9397986
[TBL] [Abstract][Full Text] [Related]
48. Transepithelial transport of drugs by the multidrug transporter in cultured Madin-Darby canine kidney cell epithelia.
Horio M; Chin KV; Currier SJ; Goldenberg S; Williams C; Pastan I; Gottesman MM; Handler J
J Biol Chem; 1989 Sep; 264(25):14880-4. PubMed ID: 2570070
[TBL] [Abstract][Full Text] [Related]
49. Evidence for a non-MDR1 component in digoxin secretion by human intestinal Caco-2 epithelial layers.
Lowes S; Cavet ME; Simmons NL
Eur J Pharmacol; 2003 Jan; 458(1-2):49-56. PubMed ID: 12498906
[TBL] [Abstract][Full Text] [Related]
50. A mechanistic study on reduced toxicity of irinotecan by coadministered thalidomide, a tumor necrosis factor-alpha inhibitor.
Yang XX; Hu ZP; Xu AL; Duan W; Zhu YZ; Huang M; Sheu FS; Zhang Q; Bian JS; Chan E; Li X; Wang JC; Zhou SF
J Pharmacol Exp Ther; 2006 Oct; 319(1):82-104. PubMed ID: 16815871
[TBL] [Abstract][Full Text] [Related]
51. Intestinal absorption mechanisms of 2'-deoxy-2'-β-fluoro-4'-azidocytidine, a cytidine analog for AIDS treatment, and its interaction with P-glycoprotein, multidrug resistance-associated protein 2 and breast cancer resistance protein.
Liu Y; Liu B; Zhang Y; Peng Y; Huang C; Wang N; Jiang J; Wang Q; Chang J
Eur J Pharm Sci; 2017 Jul; 105():150-158. PubMed ID: 28487144
[TBL] [Abstract][Full Text] [Related]
52. Role of P-glycoprotein in deoxynivalenol-mediated in vitro toxicity.
Ivanova L; Fæste CK; Solhaug A
Toxicol Lett; 2018 Mar; 284():21-28. PubMed ID: 29174985
[TBL] [Abstract][Full Text] [Related]
53. Region-dependent modulation of intestinal permeability by drug efflux transporters: in vitro studies in mdr1a(-/-) mouse intestine.
Stephens RH; Tanianis-Hughes J; Higgs NB; Humphrey M; Warhurst G
J Pharmacol Exp Ther; 2002 Dec; 303(3):1095-101. PubMed ID: 12438532
[TBL] [Abstract][Full Text] [Related]
54. Application and limitation of inhibitors in drug-transporter interactions studies.
Wang Q; Strab R; Kardos P; Ferguson C; Li J; Owen A; Hidalgo IJ
Int J Pharm; 2008 May; 356(1-2):12-8. PubMed ID: 18272304
[TBL] [Abstract][Full Text] [Related]
55. Transport characteristics of tryptanthrin and its inhibitory effect on P-gp and MRP2 in Caco-2 cells.
Zhu X; Zhang X; Ma G; Yan J; Wang H; Yang Q
J Pharm Pharm Sci; 2011; 14(3):325-35. PubMed ID: 21824448
[TBL] [Abstract][Full Text] [Related]
56. Vectorial transport of fexofenadine across Caco-2 cells: involvement of apical uptake and basolateral efflux transporters.
Ming X; Knight BM; Thakker DR
Mol Pharm; 2011 Oct; 8(5):1677-86. PubMed ID: 21780830
[TBL] [Abstract][Full Text] [Related]
57. Role of P-glycoprotein in intestinal absorption of FB2, a promising Abl/Src dual tyrosine kinase inhibitor.
Huang K; Hu J; Li X; Li Y
Drug Metab Pharmacokinet; 2012; 27(5):486-94. PubMed ID: 22447116
[TBL] [Abstract][Full Text] [Related]
58. P-glycoprotein efflux pump expression and activity in Calu-3 cells.
Hamilton KO; Backstrom G; Yazdanian MA; Audus KL
J Pharm Sci; 2001 May; 90(5):647-58. PubMed ID: 11288109
[TBL] [Abstract][Full Text] [Related]
59. Role of glutathione conjugate efflux in cellular protection against benzo[a]pyrene-7,8-diol-9,10-epoxide-induced DNA damage.
Srivastava SK; Watkins SC; Schuetz E; Singh SV
Mol Carcinog; 2002 Mar; 33(3):156-62. PubMed ID: 11870881
[TBL] [Abstract][Full Text] [Related]
60. The systemic exposure of an N-methyl-D-aspartate receptor antagonist is limited in mice by the P-glycoprotein and breast cancer resistance protein efflux transporters.
Polli JW; Baughman TM; Humphreys JE; Jordan KH; Mote AL; Webster LO; Barnaby RJ; Vitulli G; Bertolotti L; Read KD; Serabjit-Singh CJ
Drug Metab Dispos; 2004 Jul; 32(7):722-6. PubMed ID: 15205387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
